Vaccines appear in the public health and epidemic prevention zone, multinational giants accelerate their deployment in the Chinese market
This year is a special year, and the display of anti-epidemic achievements related to the epidemic has naturally become one of the keywords of the third CIIE.
In particular, vaccines, which are indispensable in disease prevention, have become a highlight in the public health epidemic prevention zone.
CBN reporters learned during the interview that in addition to other vaccines for the prevention and control of infectious diseases that have already been commercialized, the CIIE will also showcase a number of potential vaccine projects under development against the new coronavirus.
Wang Binjie, assistant to the general manager of the Exhibition Department of the National Exhibition and Convention Center (Shanghai) International Import Expo, introduced that in combination with the hot spots of the prevention and control of the new crown pneumonia epidemic, the third CIIE set up a "public health and epidemic prevention zone" in the medical exhibition area to intensively display international advanced public health and epidemic prevention products , Technology, services and hot products that play an important role in the prevention and control of new coronary pneumonia.
Important highlights of the vaccine-related anti-epidemic exhibition area
According to the introduction, multinational pharmaceutical giants such as AstraZeneca, Sanofi, Pfizer, Johnson & Johnson, and Merck have participated in the China International Import Expo for three consecutive times, but they all appeared in the form of dual booths for the first time.
Wang Lei, AstraZeneca's global executive vice president and president of international business and China, introduced in an interview with media including China Business News that in the anti-epidemic exhibition area, the company will showcase the phased results of the new crown vaccine cooperation with Oxford University.
Although this vaccine has had patient adverse reactions in the United Kingdom and Brazil before, after analyzing the cases, the clinical practice in various countries has gradually recovered and has been considered an isolated event. In this phase of the CIIE report, It also hopes to import Oxford technology into China.
In early August this year, Kangtai Biological announced that AstraZeneca exclusively authorized the company to conduct research and development, production and commercialization of licensed products in the People’s Republic of China (excluding Hong Kong Special Administrative Region, Macau Special Administrative Region, and Taiwan), and stated that the company will ensure It will have sufficient capacity to produce at least 100 million doses per year by the end of 2020 and at least 200 million doses per year by the end of 2021.
As of October 20, Kangtai Biotech stated in the interactive platform to communicate with investors that the cooperation between the company and AstraZeneca is currently in the technology transfer stage.
Sanofi set up the theme booth of "Smart Public Health City" in the anti-epidemic exhibition area, with modules such as smart public health city management platform, publicly funded vaccine solutions, vaccine life-cycle protection, and smart unmanned vaccination cabin. Shows the concept of scientific management of public health.
Among them, in the vaccine solution, Sanofi will demonstrate the concept of smart unmanned vaccination chamber for the first time.
According to the introduction, the intelligent unmanned vaccination cabin is supported by artificial intelligence and other technologies, and integrates the vaccination "three checks, seven pairs, one verification" operation specifications, remote public health physician support, low-temperature vaccine storage, full traceability, automatic vaccine Functions such as vaccination, wearable observation, and automatic disinfection can maximize the automation and unmanned vaccination, thus becoming an effective boost for vaccination clinics and a strong support for the establishment of vaccine epidemic prevention barriers in smart public health cities.
Pfizer will display the past and present of vaccines in the form of a full product chain of vaccines in the public health and epidemic prevention zone and the company's future layout in the vaccine field.
Che Yan, head of Pfizer China's vaccine marketing department, introduced to the media including China Business News that the 20-valent pneumococcal polysaccharide conjugate vaccine developed on the basis of the 13-valent pneumococcal polysaccharide conjugate vaccine is aimed at preventing epidemic meningitis. Innovative products such as the meningococcal conjugate vaccine will be displayed in this CIIE.
In more than 120 countries around the world, the 13-valent pneumococcal polysaccharide conjugate vaccine has been vaccinated for the whole population, but in my country, only the indication for children under 2 years of age has been approved.
China has entered an aging society, and the elderly need vaccines to prevent pneumococcal diseases.
Che Yan said that Pfizer will work with government agencies and industry experts to promote the availability of innovative vaccines at the public health and epidemic prevention booth.
The veteran pharmaceutical company Merck will review the history of human anti-poliomyelitis, various influenza viruses, HIV viruses, hepatitis B and hepatitis C virus in the form of a "100-year history of anti-epidemic" exhibition hall, as well as the new crown pneumonia vaccine and a new crown oral antiviral drug EIDD -2801.
Multinational giants accelerate their deployment in the Chinese market
In recent years, with the continuous advancement of the Healthy China 2030 Plan, China's healthcare market has also attracted more and more multinational companies to accelerate their deployment.
Wang Lei said that AstraZeneca’s booth at the CIIE has been expanding every year, from 500 square meters in the first session to 800 square meters in the second session, and this year's third session is already 1,000 square meters.
"I think AstraZeneca will definitely book better booths and larger booths at the future CIIE. This also shows AstraZeneca's determination, because AstraZeneca has achieved fruitful results through the CIIE every year. In the CIIE, we will sign many import projects and reach important strategic partnership agreements with domestic medical institutions and various provinces and cities." Wang Lei said.
Johnson & Johnson, which has entered the Chinese market for 35 years, expressed that it will continue to enhance China's position as the number one global business development engine, and work with partners from all walks of life to build China into a global innovation engine.
Johnson & Johnson stated in its written feedback to reporters that as one of the first foreign-funded companies to announce its participation in the CIIE, the company will still accelerate the introduction of innovative products and the implementation of innovative solutions.
We also look forward to accelerating the introduction of more world-leading medical device products and consumer products into the Chinese market with the support of favorable national policies, and responding to the market more agilely through Johnson & Johnson’s continuously upgraded intelligent manufacturing capabilities and end-to-end global supply chain system in the Chinese market demand.
Dan Brindle, President of Novartis Group (China), pointed out to CBN that China has become one of Novartis' most strategic and important markets.
Even if affected by the outbreak of the new crown pneumonia epidemic, Novartis has full confidence in the Chinese market and we believe that the market fundamentals are still good.
China is currently Novartis's third largest market in the world, and Novartis expects that China will become the world's second largest market in the future.
During 2020-2024, Novartis expects to submit 50 new drug applications in China.
Even if affected by the outbreak of the new crown pneumonia epidemic, Novartis has full confidence in the Chinese market and we believe that the market fundamentals are still good.
As an important platform to promote international trade exchanges and release signals of open cooperation, the CIIE will undoubtedly provide multinational companies with opportunities to further explore the Chinese market and tap more business opportunities.
In the first half of the year, AbbVie, which has just completed an expensive merger in medical history, will use the CIIE as a platform to showcase its new image as a global pharmaceutical giant.
AbbVie China's general manager Osslang told CBN reporters that the scheduled holding of this CIIE demonstrates the Chinese government’s determination to open up and cooperate with the world as always, which is in line with AbbVie’s long-term innovation-driven leadership. The concepts of breakthrough and win-win cooperation coincide, and AbbVie is full of expectations for this CIIE.
Author: Lv Jinyu